Rui Cheng

Dr. Rui Cheng


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2024 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
LQLinrui Qi
Linrui Qi
XGxin geng
xin geng
RFRongliang Feng
Rongliang Feng
SWShuaishuai Wu
Shuaishuai Wu
TFTengyue Fu
Tengyue Fu
XWXiangyu Wang
Xiangyu Wang

7 May 2021 in Diagnostic and Interventional Radiology
Verified
Journal Article
Closed access
JGJing Guo
Jing Guo
JRJialiang Ren
Jialiang Ren
BCBeijing Ge Healthcare China
Beijing Ge Healthcare China
JSJunkang Shen
Junkang Shen
RCRui Cheng
Rui Cheng
YHYexin He
Yexin He
We aimed to explore whether multiparametric magnetic resonance imaging (MRI)-based radiomics combined with selected blood inflammatory markers could effectively predict the grade and proliferation in glioma patients. This retrospective study included 152 patients histopathologically diagnosed with glioma. Stratified sampling was used to divide all patients into a training cohort (n=107) and a validation cohort (n=45) according to a ratio of 7:3, and five-fold repeat cross-validation was adopted in the training cohort. Multiparametric MRI and clinical parameters, including age, the neutrophil-lymphocyte ratio and red cell distribution width, were assessed. During image processing, image registration and gray normalization were conducted. A radiomics analysis was performed by extracting 1584 multiparametric MRI-based features, and the least absolute shrinkage and selection operator (LASSO) was applied to generate a radiomics signature for predicting grade and Ki-67 index in both training and validation cohorts. Statistical analysis included analysis of variance, Pearson correlation, intraclass correlation coefficient, multivariate logistic regression, Hosmer-Lemeshow test, and receiver operating characteristic (ROC) curve. The radiomics signature demonstrated good performance in both the training and validation cohorts, with areas under the ROC curve (AUCs) of 0.92, 0.91, and 0.94 and 0.94, 0.75, and 0.82 for differentiating between low and high grade gliomas, grade III and grade IV gliomas, and low Ki-67 and high Ki-67, respectively, and was better than the clinical model; the AUCs of the combined model were 0.93, 0.91, and 0.95 and 0.94, 0.76, and 0.80, respectively. Both the radiomics signature and combined model showed high diagnostic efficacy and outperformed the clinical model. The clinical factors did not provide additional improvement in the prediction of the grade and proliferation index in glioma patients, but the stability was improved.

15 February 2023 in Medicina
Verified
Journal Article
Open access
PDF file
XYXiaohui Yao
Xiaohui Yao
QLQian Liu
Qian Liu
SZSida Zhao
Sida Zhao
RCRui Cheng
Rui Cheng
CLChunhui Liu
Chunhui Liu
GZGangli Zhang
Gangli Zhang
Background and Objective: Non-functioning pituitary neuroendocrine tumors (NF-PitNETs) represent a heterogeneous tumor type that lacks effective medical treatment. MDM2, the main negative regulator of p53, binds to and forms a stable complex with p53 to regulate its activity. In this study, we measured the expression levels and role of MDM2 in non-functioning PitNET patients’ combined clinical features and investigated the effect of etoposide on the cell bioactivity of the GT1-1 cell line in vivo and in vitro. Methods: RT-PCR and immunochemistry measured the expression levels and role of MDM2 in 103 NF-PitNET patients’ combined clinical features. Cell proliferation, migration, colony and apoptosis experiments measured the effect of etoposide on the GT1-1 cell line in vivo and in vitro. Results: There was more invasive behavior (p = 0.013) in patients with high MDM2, who were also younger (p = 0.007), were more frequently female (p = 0.049) and had larger tumor sizes (p = 0.018) compared with patients with low MDM2. Patients with high p53 were younger (p = 0.017) and had larger tumor sizes (p = 0.034) compared with patients with low p53. Univariate (p = 0.018) and multivariate (p = 0.023) Cox regression analysis showed that MDM2 was the independent factor for invasive behavior in NF-PitNET patients. Log-rank analysis showed that the average progression-free survival (PFS) time in the low MDM2 patients was longer than that in the high MDM2 patients (p = 0.044). Functional studies indicated that etoposide inhibited cell proliferation and cell migration and induced apoptosis in p53 independence in GT1-1 cells. Furthermore, etoposide significantly inhibited the growth of GT1-1-xenograft in BALB/c nude mice. The tumor growth inhibition rate of etoposide was 67.4 ± 4.6% after 14 d of treatment, which suggested the anti-tumor activity of etoposide. Conclusions: MDM2 played the role of tumorigenesis of NF-PitNET in a p53 independence manner, and an MDM2 inhibitor could be a potential choice for the treatment of NF-PitNET patients.

21 November 2023 in Neurosurgical Review
Verified
Journal Article
Closed access
PDF file
XGxin geng
xin geng
Hao WuHao Wu
Hao Wu
CLChen an Liu
Chen an Liu
LQLinrui Qi
Linrui Qi
ABAugustine K Ballah
Augustine K Ballah
XWXiangyu Wang
Xiangyu Wang

23 May 2022 in IEEE Transactions on Instrumentation and Measurement
Verified
Journal Article
Closed access
YYYun Yang
Yun Yang
RCRui Cheng
Rui Cheng
JHJian He
Jian He
CLChuncheng Li
Chuncheng Li
XQXiaojun Qiao
Xiaojun Qiao
XCXiujian Chou
Xiujian Chou
A skiing monitoring system composed of multiple sensors can feedback videos, kinematic, and physiological parameters synchronously. Also, it is a significant technology for improving the skills of skiers. The time synchronization between diverse sensors is a prerequisite for comprehensive analysis and feedback. The global navigation satellite system (GNSS) and the inertial measurement unit (IMU) sensor are the two key components of the skiing monitoring system. However, due to uncertainties in the quasi-random human motion signals of skiing, it is still a challenge to achieve fully automatic synchronization between the GNSS and independent IMU without imposing any additional burden on skiers. In order to provide a solution that can be used in daily ski training, a time synchronization algorithm based on cross correlation analysis and “0/1 speed dichotomy” (CSD) is proposed. For the first time, the quasi-random human motion signals of skiing collected by the GNSS and independent IMU achieve automatic time synchronization without imposing any additional burden to the athletes. In this method, the sampling points of IMU and GNSS are divided into static state interval and motion state interval by a static interval detection algorithm, and then, the speed is assigned a value of 0 or 1 depending on the interval in which the sample point is located. It is no longer necessary to reconstruct the speed by integration operation using the acceleration collected by IMU. The algorithm is verified by using 21 training datasets from ten national athletes. The results show that even in the presence of ski resorts and athletes changing, the average error of CSD is 84.65 ms and the average running time of CSD is only 58.77 ms. The average error is further reduced to 34.29 ms with a standard deviation of 33.64 ms when the sampling rates of GNSS and IMU are increased. Compared to time synchronization algorithms based on high-pass filters, zero velocity update (ZUPT), and improved ZUPT, CSD takes less time to run with smaller synchronization errors and standard deviations when test athletes and snowfields change. CSD shows distinct advantages, including low computational cost, good robustness, and high accuracy. Therefore, CSD is adopted for application in a synchronous skiing monitoring system. The system can perform collection, synchronous analysis, feedback of various data, and videos of skiers without affecting the skiers’ actions. At present, the system has been used in the daily training of a professional cross-country skiing team and has provided some suggestions for athletes to improve their physical distribution and technical actions.

14 December 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Hao WuHao Wu
Hao Wu
XGxin geng
xin geng
CLChen an Liu
Chen an Liu
ABAugustine K Ballah
Augustine K Ballah
飞李飞翔 李
飞翔 李
YWYonghong Wang
Yonghong Wang
Hospital Acquired Pneumonia (HAP) is one of the most common complications and late causes of death in TBI patients. Targeted prevention and treatment of HAP are of great significance for improving the prognosis of TBI patients. In the previous clinical observation, we found that folic acid treatment for TBI patients has a good effect on preventing and treating HAP. We conducted this retrospective cohort study to demonstrate what we observed by selecting 293 TBI patients from two medical centers and analyzing their hospitalization data. The result showed that the incidence of HAP was significantly lower in TBI patients who received folic acid treatment (44.1% vs. 63.0%, p = 0.012). Multivariate logistic regression analysis showed that folic acid treatment was an independent protective factor for the occurrence of HAP in TBI patients (OR = 0.418, p = 0.031), especially in high-risk groups of HAP, such as the old (OR: 1.356 vs. 2.889), ICU (OR: 1.775 vs. 5.996) and severe TBI (OR: 0.975 vs. 5.424) patients. At the same time, cohort studies of HAP patients showed that folic acid also had a good effect on delaying the progression of HAP, such as reducing the chance of tracheotomy (26.1% vs. 50.8%, p = 0.041), and reduced the length of hospital stay (15 d vs. 19 d, p = 0.029) and ICU stay (5 d vs. 8 d, p = 0.046). Therefore, we believe that folic acid treatment in TBI patients has the potential for preventing and treating HAP, and it is worthy of further clinical research.